Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy.

Pharmacogenomics - 1 Sept 2008

Spreafico Marta, Lodigiani Corrado, van Leeuwen Y, Pizzotti Denise, Rota Lidia L, Rosendaal Fr, Mannucci Pier M, Peyvandi Flora

Abstract excerpt

INTRODUCTION: Anticoagulants of the coumarin type are effective drugs for the treatment and prevention of thromboembolic diseases. However, they have a narrow therapeutic range and show inter- and intra-individual variability in dose requirement, largely conditioned by both environmental and genetic factors. METHODS: This prospective study investigated, during the initial phase of acenocoumarol therapy, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Cytochrome P-450 CYP2C9

Share to Dose-Response Relationship, Drug

Share to International Normalized Ratio

Share to Mixed Function Oxygenases

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 18781852
DOI: 10.2217/14622416.9.9.1237

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy.PMID 18781852Read ↗

Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.Semantic proximity Read ↗

CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.Semantic proximity Read ↗

VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.Semantic proximity Read ↗

Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.Semantic proximity Read ↗

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.Semantic proximity Read ↗

Genetic determinants of response to warfarin during initial anticoagulation.Semantic proximity Read ↗

Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.Semantic proximity Read ↗

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.Semantic proximity Read ↗

Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.Semantic proximity Read ↗

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.Semantic proximity Read ↗

Pharmacogenetics role in the safety of acenocoumarol therapy.Semantic proximity Read ↗

Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.